T
Trevi Therapeutics
Develops drugs for treating uremic pruritus
About Trevi Therapeutics
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing the development and commercialization of its investigational therapy, Haduvio™ (nalbuphine ER). The company was established in 2011 by Jennifer L. Good and Dr. Thomas R. Sciascia and is headquartered in New Haven, Connecticut. The co-founders had previously worked together at Penwest Pharmaceuticals, where Ms. Good served as CEO and Dr. Sciascia was Chief Medical Officer. After Penwest was acquired, they identified the potential in nalbuphine, a compound from their former company, and negotiated to acquire it, leading to the formation of Trevi. Ms. Good, who has been President and CEO since the company's inception, brought a background in finance and accounting, including experience at Ernst & Young, while Dr. Sciascia provided the neurological expertise.
As a clinical-stage entity, Trevi Therapeutics does not yet generate revenue from product sales; its operations are funded through financing activities like stock offerings. The company successfully went public with an initial public offering (IPO) on the Nasdaq on May 7, 2019, under the ticker TRVI, raising approximately $55 million. Subsequent offerings, including a $115 million financing in June 2025, have extended the company's financial runway into 2029, supporting its late-stage clinical development. The business model is centered on advancing Haduvio through rigorous clinical trials to gain regulatory approval, which would then allow for commercialization and sales to patients. The company operates in the biopharmaceutical market, focusing on patient populations with significant unmet medical needs.
Trevi's sole product candidate, Haduvio™, is an oral extended-release formulation of nalbuphine, a drug with a long history of use for pain management. Haduvio features a dual mechanism of action, functioning as a kappa opioid receptor agonist and a mu opioid receptor antagonist. This unique profile allows it to target the body's central and peripheral nervous systems to address the underlying pathophysiology of certain conditions without the high potential for abuse associated with typical mu-opioid agonists. Initially, Trevi explored its use in multiple indications, including severe itching (pruritus) and levodopa-induced dyskinesia in Parkinson's patients. Following compelling clinical data, the company has pivoted to focus squarely on chronic cough conditions. Positive results from its Phase 2b CORAL trial in patients with idiopathic pulmonary fibrosis (IPF) and its Phase 2a RIVER trial for refractory chronic cough (RCC) have demonstrated statistically significant reductions in cough frequency, reinforcing the company's strategic direction. Trevi is now preparing for Phase 3 trials, aiming to be the first approved therapy for chronic cough in IPF patients.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2011
- Headquarters
- New Haven, United States
- Listing
- IPO 2019
- Sector
- Biotech & Life Sciences
- Outcome tier
- Unicorn$1–10B valuation tier
News
Open roles
Trevi Therapeutics in the New Haven ecosystem
The Trevi Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
TPG
TPG Biotech
Series B and later9 investors entered at this stage
Solar capital
Square 1 Bank
NEA
Lundbeckfonden VenturesOmega Funds
- APAperture Venture Partners
Frazier Healthcare Partners- VPVenrock Healthcare Capital Partners
Fairmount Funds Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
13 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Trevi Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Trevi Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

